10-Q: BiomX Faces Going Concern Doubt Amid Rising Losses

BiomX Inc. reported increased net losses and a significant decline in cash, raising substantial doubt about its ability to continue as a going concern, despite positive clinical trial results for its lead programs.

Summary

• BiomX reported a net loss of $6.037 million for the three months ended June 30, 2025, a shift from a net income of $4.471 million in the same period of 2024.
• The accumulated deficit increased to $194.393 million as of June 30, 2025, up from $180.697 million at December 31, 2024.
• Cash and cash equivalents decreased to $14.046 million as of June 30, 2025, from $16.856 million at December 31, 2024.
• Management believes current funds are not sufficient to fund operations for at least one year, raising substantial doubt about the company's ability to continue as a going concern.
• The company announced positive Phase 1b/2a results for BX004 in cystic fibrosis (CF) patients, showing safety, tolerability, and a 2.7 log CFU/g treatment effect on P. aeruginosa.
• BX004 received FDA Fast Track and Orphan Drug designations, and a Phase 2b study in CF patients was initiated with the first patient dosed on July 14, 2025, with topline readout expected in Q1 2026.
• Positive Phase 2 results were reported for BX211 in diabetic foot osteomyelitis (DFO), demonstrating statistically significant percent area reduction of ulcer size (p=0.046 at week 12) and improvements in ulcer depth (p=0.048).
• BiomX discontinued the BX005 program for Atopic Dermatitis in 2024 and paused the Prosthetic Joint Infections (PJI) program to prioritize resources on CF and DFO.
• The company completed a February 2025 financing, generating $5.527 million in gross proceeds from a registered direct offering and private placement, and an additional $6.473 million from a warrant exercise.

Sentiment

Score: 3

Explanation: While there are positive clinical trial results for key programs (BX004 and BX211), the significant net losses, increasing accumulated deficit, declining cash position, and explicit 'going concern' warning from management indicate a precarious financial situation. The capital raises in February 2025 provided some liquidity but are not sufficient for long-term operations, necessitating further capital raises in a challenging market. The discontinuation of one program and pausing of another also reflect resource constraints.

Positives

• Positive Phase 1b/2a trial results for BX004 in Cystic Fibrosis, demonstrating safety, tolerability, and a 2.7 log CFU/g treatment effect on P. aeruginosa.
• BX004 received FDA Fast Track and Orphan Drug designations, which can accelerate development and regulatory review.
• Initiation of a Phase 2b study for BX004 in CF, indicating progression towards later-stage clinical development.
• Positive Phase 2 trial results for BX211 in Diabetic Foot Osteomyelitis, showing statistically significant improvements in ulcer size reduction (p=0.046 at week 12) and ulcer depth (p=0.048).
• BX211 demonstrated comparable efficacy against both Methicillin-susceptible and resistant S. aureus strains, and against high and low biofilm producers.
• Reduced Research and Development (R&D) expenses by $1.9 million (28%) for Q2 2025 compared to Q2 2024, and by $0.7 million (6%) for H1 2025 compared to H1 2024, partly due to workforce reduction and higher grants.
• Reduced General and Administrative (G&A) expenses by $0.4 million (14%) for Q2 2025 and $0.6 million (11%) for H1 2025.
• Net cash used in operating activities decreased to $14.821 million for H1 2025 from $22.593 million for H1 2024, indicating improved operational cash burn.
• Successful February 2025 financing and warrant exercise generated $11.9 million in net cash from financing activities.

Negatives

• Reported a net loss of $6.037 million for the three months ended June 30, 2025, a significant deterioration from a net income of $4.471 million in the same period of 2024.
• The accumulated deficit increased to $194.393 million as of June 30, 2025, from $180.697 million at December 31, 2024.
• Cash and cash equivalents decreased by $2.81 million from December 31, 2024, to $14.046 million as of June 30, 2025.
• Management explicitly states that current funds are insufficient to fund operations for at least one year, raising substantial doubt about the company's ability to continue as a going concern.
• Net cash provided by financing activities significantly decreased to $11.884 million for H1 2025 from $38.772 million for H1 2024.
• Income from change in fair value of warrants decreased significantly to $1.5 million for Q2 2025 from $11.9 million for Q2 2024, and to $2.4 million for H1 2025 from $3.9 million for H1 2024.
• Basic loss per share shifted to $0.19 for Q2 2025 from earnings of $0.14 for Q2 2024.
• The BX005 program for Atopic Dermatitis was discontinued in 2024, and the Prosthetic Joint Infections (PJI) program was paused, reducing pipeline diversity.
• Potential requirement to repay $500,000 for previously reimbursed leasehold improvements if the Ness Ziona office lease is not extended.

Risks

• Ability to generate revenues and raise sufficient financing to meet working capital requirements.
• Unpredictable timing and cost associated with developing product candidates using phage technology and potential success thereof.
• Political, economic, and military instability in the State of Israel, including the war in Iran, Gaza, and Lebanon, and potential conflicts with other Middle Eastern countries.
• Continuation of proposed judicial and other legislation reform by the Israeli government.
• Political and economic instability due to natural disasters, catastrophic events (e.g., Russian invasion of Ukraine), terrorist attacks, hurricanes, fire, floods, pollution, and earthquakes.
• Obtaining U.S. Food and Drug Administration (FDA) acceptance of any non-U.S. clinical trials of product candidates.
• Ability to enroll patients in clinical trials and achieve anticipated development milestones when expected.
• Ability to pursue and effectively develop new product opportunities and acquisitions and to obtain value from such.
• Penalties and market withdrawal associated with unanticipated problems with product candidates and failure to comply with labeling and other restrictions.
• General economic conditions, current low stock price, and other factors impacting operations, business continuity, and ability to raise additional capital.
• Expenses associated with compliance with ongoing regulatory obligations and successful continuing regulatory review.
• Market acceptance of product candidates and ability to identify or discover additional product candidates.
• Ability to obtain high titers for specific phage cocktails necessary for preclinical and clinical testing.
• Availability of specialty raw materials and global supply chain challenges.
• Ability of product candidates to demonstrate requisite safety and efficacy for drug products, or safety, purity, and potency for biologics without causing adverse effects.
• Success of expected future advanced clinical trials of product candidates.
• Ability to obtain required regulatory approvals.
• Delays in developing manufacturing processes for product candidates.
• Competition from similar technologies, more effective, safer, or more affordable products, or products obtaining marketing approval before BiomX's candidates.
• Impact of unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives on profitability.
• Protection of intellectual property rights and compliance with license terms.
• Infringement on third-party intellectual property rights and claims for remuneration or royalties.
• Ability to acquire, in-license, or use proprietary rights held by third parties.
• Ethical, legal, and social concerns about synthetic biology and genetic engineering affecting market acceptance.
• Reliance on third-party collaborators.
• Ability to attract and retain key employees or enforce noncompetition agreements.
• Failure to comply with applicable laws and regulations (other than drug manufacturing).
• Potential security breaches, including cybersecurity incidents.
• Substantial doubt about the company's ability to continue as a going concern due to significant losses and negative cash flows.

Future Outlook

BiomX expects to continue incurring losses and does not anticipate significant revenue from product sales in the next twelve months. Current liquidity is estimated to fund operations into the first quarter of 2026. The company plans to seek additional funding through equity, debt, loans, and government grants. Feedback from the FDA and European Committee for Medicinal Products for Human Use regarding the use of Real-World Evidence (RWE) for BX004 is anticipated in 2025. Topline readout for the BX004 Phase 2b study is expected in Q1 2026, and a potential registrational study for BX211 is planned, pending FDA feedback and cash resources.

Management Comments

• "Management believes that its current funds are not sufficient to fund its operations for at least one year from the issuance date of these financial statements."
• "The ongoing war with Hamas, Hezbollah and Iran has not, since its inception, materially impacted BiomXs business or operations. Furthermore, BiomX does not expect any delays to its programs as a result of the situation."
• "We currently plan to continue to focus primarily on the development of BX004, our product candidate for treating CF and BX211, our product candidate for treating DFO."
• "We expect to generate revenues from the sale of licenses to use our technology or products, but in the short and medium terms any amounts generated are unlikely to exceed our costs of operations."

Industry Context

BiomX operates in the emerging field of phage therapy, a novel approach to combat bacterial infections, particularly those resistant to traditional antibiotics. This positions the company to address significant unmet medical needs in chronic diseases like Cystic Fibrosis and Diabetic Foot Osteomyelitis, where antibiotic resistance is a growing concern. The strategic focus on its most promising assets (CF and DFO) and the discontinuation of other programs reflect a common strategy for clinical-stage biotechs in a capital-constrained environment, aiming to optimize resource allocation for higher probability of success.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry benchmarking.
• The company's approach of using 'fixed cocktail therapy' and 'personalized therapy' with its proprietary BOLT platform is presented as unique, but no direct comparison to other companies' platforms is provided.
• The Fast Track and Orphan Drug designations for BX004 are standard regulatory pathways for promising therapies addressing serious conditions with unmet needs, indicating alignment with industry best practices for accelerating development.
• The statistically significant results for BX211 in DFO (p=0.046 at week 12 for PAR, p=0.048 for ulcer depth) are positive indicators for a Phase 2 trial, suggesting potential for further development, though direct comparisons to other DFO treatments are not detailed.

Legal Proceedings

• Settlement agreement with Oyster (Viatris Inc. subsidiary) regarding alleged breaches of a Collaboration and Option Agreement, resulting in a $300,000 payment from APT to Oyster on January 13, 2025.

Stakeholder Impact

• Shareholders face significant dilution risk due to ongoing capital raises and warrant exercises. The increased accumulated deficit and going concern warning pose substantial risk to investment value, with potential for future share price volatility.
• Employees may be impacted by workforce reductions, as noted in decreased salaries expenses. Geopolitical instability in Israel could affect employee safety and operations, though the company states no material impact or delays so far.
• Patients with Cystic Fibrosis and Diabetic Foot Osteomyelitis may benefit from the potential new phage therapies (BX004, BX211) addressing unmet medical needs. However, the discontinuation of BX005 and pausing of PJI programs mean these patient populations will not benefit from BiomX's therapies in the near term.
• Creditors face increased risk due to the explicit going concern warning, indicating potential challenges in repayment.
• Suppliers may face challenges related to the availability of specialty raw materials and global supply chain issues, as noted in the risk factors.

Next Steps

• Topline readout of the BX004 Phase 2b study results expected in the first quarter of 2026.
• Anticipate feedback from the FDA and European Committee for Medicinal Products for Human Use in 2025 regarding the proposed plan to use Real-World Evidence (RWE) to support potential future regulatory filings for BX004.
• Planning a potential registrational study of BX211, pending FDA feedback and availability of cash resources.
• May initiate studies into Non-CF Bronchiectasis (NCFB) as an additional indication for BX004, pending positive data from the CF Phase 2b study.
• Continue to monitor ongoing activities and make adjustments to ensure business continuity amidst geopolitical instability.
• Explore and expect to further explore raising additional funds through public or private equity, debt financing, loans, government or other grants or collaborative agreements.
• BiomX Israel is in preliminary negotiations regarding a modification to its existing lease agreement and evaluating potential alternatives for its Ness Ziona office space.

Key Dates

Recommendation

Despite positive clinical trial data for BX004 and BX211, the company faces severe financial distress, explicitly stating 'substantial doubt' about its ability to continue as a going concern. The significant net losses, increasing accumulated deficit, and rapidly declining cash reserves, coupled with the need for continuous capital raises in a challenging market, present an extremely high-risk investment profile. The positive clinical results are overshadowed by the fundamental financial instability and the high likelihood of further dilution.

Keywords

Phage therapy, Cystic Fibrosis, Diabetic Foot Osteomyelitis, Biotechnology, Clinical stage, Drug development, Antibiotic resistance, SEC filing, 10-Q, Microbiome, Israel, Biopharmaceutical